Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis

Background. PD-1/PD-L1 inhibitors have made unprecedented progress in the treatment of cancer. Methods. A systemic search was conducted for randomized controlled trials that compared PD-1/PD-L1 inhibitor monotherapy or combination therapy with nonimmunotherapy. Hazard ratios (HRs) of overall surviva...

Full description

Bibliographic Details
Main Authors:	Yuhan Wei, Yongfu Li, Qi Du, Xinyi Peng, Jiangtao Jin, Hong Guo, Yongyan Li, Qin Li
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2020/5269787

Similar Items

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-10-01)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
by: Zhijuan Lin, et al.
Published: (2016-01-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
by: Deirdre Kelly, et al.
Published: (2021-01-01)

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
by: Konstantinos Rounis, et al.
Published: (2021-03-01)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019-02-01)

The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
by: Gang Xu, et al.
Published: (2019-09-01)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
by: Yanhua Bai, et al.
Published: (2017-10-01)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021-06-01)

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
by: Magdalena Zajac, et al.
Published: (2020-01-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis
by: Ling Lu, et al.
Published: (2020-04-01)

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
by: Yu Zhang, et al.
Published: (2021-03-01)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
by: Rawad Elias, et al.
Published: (2018-04-01)

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis
by: Lei Zhu, et al.
Published: (2019-08-01)

Germline Variation in <i>PDCD1</i> Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
by: Mirjam de With, et al.
Published: (2021-03-01)

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
by: Margarita Majem, et al.
Published: (2021-03-01)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
by: Ding X, et al.
Published: (2019-05-01)

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy
by: Jian-Guo Zhou, et al.
Published: (2021-04-01)

Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
by: Ya-fang Huang, et al.
Published: (2019-10-01)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
by: Pedro Barata, et al.
Published: (2020-10-01)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
by: Hui Yang, et al.
Published: (2020-03-01)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
by: Bi‐Cheng Wang, et al.
Published: (2019-10-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
by: Shan Li, et al.
Published: (2020-01-01)

PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
by: Pin Wu, et al.
Published: (2015-01-01)

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
by: Run-Cong Nie, et al.
Published: (2021-03-01)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
by: Jee Hee Yoon, et al.
Published: (2021-04-01)

Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Hongmei Liu, et al.
Published: (2020-10-01)

PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials
by: Zhong Maoxi, et al.
Published: (2021-01-01)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
by: Yuqian Feng, et al.
Published: (2021-02-01)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
by: Jue Zhu, et al.
Published: (2021-08-01)

Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis
by: Qinfen Xie, et al.
Published: (2020-01-01)

228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy
by: Xiaoling Yang, et al.
Published: (2020-11-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
by: Ming Yi, et al.
Published: (2018-08-01)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
by: Jingwei Liu, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_pdefp3ckdj7beg0otpiaicsgos